Authors: | Dispenzieri, A.; Merlini, G.; Comenzo, R. L. |
Article Title: | Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego) |
Abstract: | AL amyloidosis is a rare disease in which immunoglobulin light chains are deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. The risks that patients with amyloidosis face include late diagnosis, misdiagnosis of amyloid type, untimely and ineffective therapy, and toxicities of therapy. The goals of treatment are (1) reduction or elimination of the amyloid-forming protein, usually a free immunoglobulin light chain measured by the serum-free light chain assay; (2) support of the patient pending hematologic response and improvement; and (3) stabilization of organ function. Whenever possible, patients should be treated on clinical trials. © 2008 American Society for Blood and Marrow Transplantation. |
Keywords: | immunohistochemistry; overall survival; lenalidomide; prednisone; thalidomide; clinical trial; drug tolerability; fatigue; mortality; dose response; unspecified side effect; antineoplastic agents; drug megadose; low drug dose; bortezomib; multiple cycle treatment; bone marrow suppression; cyclophosphamide; dexamethasone; melphalan; amyloidosis; hematopoietic stem cell transplantation; drug dose escalation; survival time; symptom; thromboembolism; stem cell mobilization; beta 2 microglobulin; biopsy technique; drug dose regimen; immunoglobulin light chain; brain natriuretic peptide; troponin i; amino terminal pro brain natriuretic peptide; troponin t |
Journal Title: | Biology of Blood and Marrow Transplantation |
Volume: | 14 |
Issue: | 1 Suppl. |
ISSN: | 1083-8791 |
Publisher: | Elsevier Inc. |
Date Published: | 2008-01-01 |
Start Page: | 6 |
End Page: | 11 |
Language: | English |
DOI: | 10.1016/j.bbmt.2007.10.026 |
PUBMED: | 18162215 |
PROVIDER: | scopus |
PMCID: | PMC2330327 |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 17 November 2011" - "CODEN: BBMTF" - "Source: Scopus" |